CA
NZ
UK
AU
IND
US
The U.S. Food and Drug Administration’s decision on May 5th—announced jointly by Daiichi Sankyo Co. (TYO: 4568) and AstraZeneca plc (LSE: AZN)—marks the first time an antibody-drug conjugate has been approved for early-stage HER2-positive breast cancer in both the neoadjuvant (pre-surgery) and adjuvant (post-surgery) …
Roche (SIX: ROG) has taken a calculated step to broaden access to its antiviral flu treatment, Xofluza (baloxavir marboxil), by inking a voluntary licensing deal with the Geneva-based Medicines Patent Pool (MPP). The agreement—announced on May 18th, 2026—grants generic manufacturers in 129 low- and …
A First-in-Class Drug That Could Reshape Hypertension Treatment
Bristol Myers Squibb (NYSE: BMY) has vaulted to the front of the pharmaceutical industry’s AI adoption curve by signing a multi-year strategic agreement with Anthropic to deploy its Claude Enterprise platform across global workflows. The deal—unveiled on Wednesday—marks a decisive shift from fragmented, department-level …
UCB (Euronext Brussels: UCB) has deepened its claim on the psoriasis market after releasing detailed data from a head-to-head psoriatic-arthritis trial showing Bimzelx’s superiority over AbbVie’s (NYSE: ABBV) Skyrizi. In the study, 49% of patients treated with Bimzelx achieved a 75% reduction in disease-activity …
A federal jury in Philadelphia delivered a historic blow to Takeda Pharmaceutical Company Limited on May 21st, ordering the Japanese drugmaker to pay $885m for orchestrating what prosecutors described as an illegal “pay-for-delay” scheme around its constipation drug Amitiza—used by roughly 3m Americans annually. …
Key HighlightsPharmaMarketingis pivoting from broad campaigns to targeted, consent-based engagement—amid a 1.7m strong HCP audience (Fierce Pharma, 2026)Audio marketing—including podcasts—is gaining traction as a way to cut through information saturation for healthcare professionalsBrands are shifting from promotional messaging to partnerships built on trust, per …
Geopolitical Risk Drives the Rebound
A Plan Built on Scale, Not Simplicity
Peace Hopes Fade, Safe Haven Narrative Fractures
Please wait processing your request...